EATG » Tuberculosis

Tuberculosis

U.S. Senate agrees on global health funding

On June 29, 2016 the Senate Appropriations Committee approved the FY 2017 State and Foreign Operations Appropriations bill, which includes funding for U.S. global health programs. Click here to read…

Aidspan publishes new issue of ‘Global Fund Observer’

Aidspan: Global Fund Observer Aidspan, an independent watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, published Issue 291 of the “Global Fund Observer.” The newsletter features articles…

European Members of Parliament convene to accelerate political progress against tuberculosis

Parliamentarians from 12 European and Central Asian countries convened in Bratislava from 24-26 June for the European TB Summit, issuing a united call for governments to put tuberculosis (TB) back…

Researcher receives grant to understand why some individuals with HIV avoid ‘duet of death’

Findings could offer hope for TB prevention, cure Case Western Reserve University School of Medicine experts and colleagues in the United States and Africa have received an $11 million, five-year…

Tuberculosis and the right to health

Health and Human Rights Journal Special Section on tuberculosis and the right to health TB has surpassed HIV as the top infectious disease killer in the world and the global…

France pledges €1.08 billion to Global Fund

PARIS - The Government of France announced today (June 26) it will contribute €1.08 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria for the three-year period beginning…

Italy makes strong commitment to Global Fund

ROME - The Government of Italy announced today (June 27) a pledge of €130 million to the Global Fund to Fight AIDS, Tuberculosis and Malaria for the three-year period beginning…

Faster detection of pathogens in the lungs

What used to take several weeks is now possible in two days: Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much…

Aeras provides update on Phase 2 trial of H4:IC31

H4:IC31 is a novel TB vaccine candidate being developed jointly by Aeras and Sanofi Pasteur. Phase 2 trial (C-040-404/TUB09) of H4:IC31 is designed to evaluate BCG and H4:IC31 for the…

Call to Action to accelerate access to DR-TB drugs: 2016 update

The update informs about the general progress in the introduction of bedaquiline and delamanid in TB programs worldwide and reports on the requests made in the Call to Action issued…